Microplastics and Misinformation: What Science Really Says
November 12, 2025
Brand Name :
trimspa
Synonyms :
Trimébutine, Trimebutino, Trimebutine
Class :
Calcium Channel Blockers and Bradycardia-Causing Agents
Dosage forms & strengthsÂ
TabletsÂ
100 mgÂ
SpasmÂ
It is recommended for smooth muscle relaxantionÂ
300-600mg/day divided into 3 doses a day Â
N/AÂ
Refer adult dosingÂ
may have an increased CNS depressant effect when combined with opioid agonists
may have an increased CNS depressant effect when combined with opioid agonists
may have an increased CNS depressant effect when combined with opioid agonists
may have an increased CNS depressant effect when combined with opioid agonists
may have an increased CNS depressant effect when combined with opioid agonists
it increases the effect of neuromuscular blockage of neuromuscular-blocking agents
it increases the effect of neuromuscular blockage of neuromuscular-blocking agents
it increases the effect of neuromuscular blockage of neuromuscular-blocking agents
it increases the effect of neuromuscular blockage of neuromuscular-blocking agents
it increases the effect of neuromuscular blockage of neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
combining trimebutine with ipratropium may enhance the likelihood or intensity of side effects
the risk or severity of hyperkalemia may increase when isoxicam is combined with trimebutine
the use of trimebutine in combination with rimonabant increases the risk or severity of tachycardia and drowsiness
there is potential for trimebutine to enhance the neuromuscular blocking activities of tubocurarine
may decrease trimebutine elimination, raising serum levels
may have an increased analgesic effect when combined with opioid agonists
may have an increased analgesic effect when combined with opioid agonists
may have an increased analgesic effect when combined with opioid agonists
may have an increased analgesic effect when combined with opioid agonists
may have an increased analgesic effect when combined with opioid agonists
the risk of hyperkalemia may be increased
the risk of hyperkalemia may be increased
Action and spectrum:Â
Limited information availableÂ
Adverse effects:Â
Frequency not definedÂ
Dry skinÂ
Slow heart rateÂ
Dilatation of pupilÂ
Loss of accommodationÂ
PhotophobiaÂ
Black box warning:Â
NoneÂ
Pregnancy consideration:Â Â
USFDA pregnancy category: N/AÂ
Lactation:Â Â
unknownÂ
Pregnancy categories:Â Â
Pharmacology:Â
Trimebutine affects the gastrointestinal tract by modulating gastrointestinal motility through peripheral opioid receptors. It also affects the central nervous system by regulating visceral pain perception potentially reducing discomfort associated with gastrointestinal disorders.Â
PharmacokineticsÂ
AbsorptionÂ
Well absorbedÂ
DistributionÂ
It is widely distributed.Â
MetabolismÂ
Metabolized in liver.Â
ExcretionÂ
Excreted through urineÂ
Administration:Â
Given orally daily 3 times in divided doses.Â
Patient leaflet information:Â
Why do we use Trimebutine?Â
Trimebutine manages gastrointestinal disorders by reducing abdominal pain and abnormal motility. It modulates opioid receptors and blocks calcium channels making it well-tolerated.Â